Breaking the GLP-1 Cost Cycle
- White Papers
- GLP-1s
- October 17
- 1 min read
Summary
Noom’s Breaking the GLP-1 Cost Cycle white paper dives into the scale of the obesity crisis and how Noom’s two tailored solutions can enhance health outcomes and cost savings, including for those on GLP-1s or other anti-obesity medications.
Obesity is a complex, multifactorial disease that requires comprehensive medical attention and innovative treatment strategies. Within the next five years, we anticipate a seismic shift in healthcare: most organizations will extend coverage for GLP-1 medications to treat obesity. This change is inevitable as non-branded alternatives emerge and costs decrease.
To meet diverse employer needs, Noom is unveiling two tailored solutions, which can be supported either through an organization’s current pharmacy benefit manager (PBM) or through a full carve-out for GLP-1 weight loss medications. Both enable affordable access to GLP-1 medications.
- Solution 1, Noom Med with an optional SmartRx plan, is designed to drive ROI for employers who cover GLP-1s.
- Solution 2, Noom Weight with discounted access to employee-pay meds, is designed as a workforce-friendly, budget-conscious solution for employers who do not cover GLP-1s.
In our latest white paper, you’ll learn more about Noom’s solutions, and how to significantly boost your ROI and broaden access to GLP-1s now, regardless of your organization’s current coverage policies for obesity medications.
At Noom, we do not wait for tomorrow—we act today. Download now and find out how Noom helps address diverse employer needs while positioning you ahead of the curve as treatment options evolve.
Download the White Paper
By submitting this form, I understand that Noom will process my personal information in accordance with their Privacy Policy.
